DE10019052A1 - Use of polyunsaturated fatty acids for the treatment of enuresis and incontinence - Google Patents

Use of polyunsaturated fatty acids for the treatment of enuresis and incontinence

Info

Publication number
DE10019052A1
DE10019052A1 DE2000119052 DE10019052A DE10019052A1 DE 10019052 A1 DE10019052 A1 DE 10019052A1 DE 2000119052 DE2000119052 DE 2000119052 DE 10019052 A DE10019052 A DE 10019052A DE 10019052 A1 DE10019052 A1 DE 10019052A1
Authority
DE
Germany
Prior art keywords
fatty acids
acid
incontinence
polyunsaturated fatty
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE2000119052
Other languages
German (de)
Inventor
Klaus Brill
Elmar W J Weiler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
K. D. PHARMA BEXBACH GMBH, 66450 BEXBACH, DE
NEURONET INSTITUT FUER HIRNFORSCHUNG & ANGEWAN, DE
Original Assignee
BITEC GmbH
NEURONET INST fur HIRNFORSCHU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE10006836A priority Critical patent/DE10006836B4/en
Priority claimed from DE10006836A external-priority patent/DE10006836B4/en
Application filed by BITEC GmbH, NEURONET INST fur HIRNFORSCHU filed Critical BITEC GmbH
Priority to DE2000119052 priority patent/DE10019052A1/en
Priority to EP01108445A priority patent/EP1147769A3/en
Publication of DE10019052A1 publication Critical patent/DE10019052A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Polyunsaturated fatty acids are used for the treatment of enuresis and incontinence. Treatment of enuresis and incontinence comprises administration of one or more polyunsaturated fatty acids (PUFAs) and/or their derivatives.

Description

Zusatz zu 100 06 836.7Addition to 100 06 836.7

Die Erfindung betrifft eine Verwendung von mehrfach ungesättigten Fettsäuren, insbeson­ dere Omega-3-Fettsäuren.The invention relates in particular to the use of polyunsaturated fatty acids their omega-3 fatty acids.

Von den mehrfach ungesättigten Fettsäuren sind verschiedene gesundheitsfördernde Wir­ kungen bekannt. So wird ein im Handel befindliches Arzneimittel mit Wirkstoff Lachsöl-Kon­ zentrat für folgende Anwendungsgebiete empfohlen: Günstiger Einfluß auf das Blutfettsystem (Cholesterin, Triglyceride, LDL und HDL), auf die Gerinnungseigenschaften und die Fließfähig­ keit des Blutes, auf das Blutdruckverhalten und auf die Leistung des Gehirns, z. B. die Kon­ zentrations- und Lernfähigkeit.Of the polyunsaturated fatty acids, we are different health-promoting known. So is a commercially available drug with active ingredient salmon oil Kon recommended for the following areas of application: Favorable influence on the blood fat system (Cholesterol, triglycerides, LDL and HDL), on the coagulation properties and the flowability speed of blood, blood pressure behavior and brain performance, e.g. B. the Kon ability to concentrate and learn.

In DMW (Deutsche medizinische Wochenschrift) 1990, Seiten 224 bis 231 wird über Behand­ lungen der Atherosklerose und chronisch entzündlicher Erkrankungen sowie über weitere Untersuchungen berichtet.In DMW (German Medical Weekly Journal) 1990, pages 224 to 231 about Treat lungs of atherosclerosis and chronic inflammatory diseases as well as other Investigations reported.

Inhalt der Hauptanmeldung ist, daß die mehrfach ungesättigten Fettsäuren und ihre Verbin­ dungen, wie überraschend gefunden wurde, zur erfolgreichen Behandlung von Bettnässen verwendet werden können.The content of the main application is that the polyunsaturated fatty acids and their verb surprisingly found to successfully treat bedwetting can be used.

Von dem Bettnässen, Enuresis, als der unwillkürlichen Blasenentleerung, wird die Inkontinenz unterschieden als das Unvermögen, den Harn willkürlich zurückzuhalten.From bedwetting, enuresis, to involuntary voiding, incontinence distinguished as the inability to hold urine at random.

Die Mechanismen sind nicht gleich, überschneiden sich aber. The mechanisms are not the same, but overlap.  

Wie sich jetzt an bisher zwei Probanden gezeigt hat, üben die mehrfach ungesättigten Fett­ säuren und ihre Verbindungen auch bei der Inkontinenz eine Besserungswirkung aus.As has been shown in two test subjects so far, they practice polyunsaturated fat acids and their compounds also improve the effects of incontinence.

Die vorliegende Zusatzerfindung besteht also in einer Erweiterung der Haupterfindung auf die Anwendung mindestens einer mehrfach ungesättigten Fettsäure und/oder mindestens einer Verbindung einer solchen Fettsäuren zur therapeutischen Behandlung von Inkontinenz.The present additional invention therefore consists of an expansion of the main invention the use of at least one polyunsaturated fatty acid and / or at least a compound of such fatty acids for the therapeutic treatment of incontinence.

Die in der Hauptanmeldung konkreter angegebenen Stoffe und Präparate sollen auch zur Behandlung von Inkontinenz verabreicht werden.The substances and preparations specified in the main application are also intended for Treatment for incontinence can be administered.

Ein für die erfindungsgemäße Verwendung geeignetes Präparat wird in der Regel, wie bisher, aus Fischöl mit hohen Anteilen an Omega-3-Fettsäuren hergestellt sein.A preparation suitable for the use according to the invention is usually, as before, be made from fish oil with high levels of omega-3 fatty acids.

Im Falle eines bloßen Fischöl-Konzentrats liegen die Fettsäuren dann in der Verbindung der Triglyceride vor.In the case of a mere fish oil concentrate, the fatty acids are then in the compound of Triglycerides.

Höher angereicherte Produkte bestehen, je nach angewandtem Verfahren, aus den Fett­ säuren selbst oder Estern oder anderen Verbindungen der Fettsäuren. Vor allem in Betracht stehen die Stearidonsäure 18 : 4, die Eicosatetraensäure 20 : 4 (Omega 3), die Eicosapentaen­ säure 20 : 5, die Docosapentaensäure 22 : 5 und die Docosahexaensäure 22 : 6 sowie Verbin­ dungen dieser Säuren.Depending on the process used, products with a higher enrichment consist of fat acids themselves or esters or other compounds of the fatty acids. Mostly considered are the stearidonic acid 18: 4, the eicosatetraenoic acid 20: 4 (omega 3), the eicosapentaen acid 20: 5, docosapentaenoic acid 22: 5 and docosahexaenoic acid 22: 6 and verbin of these acids.

Bei den Probanden eingesetzt wurde ein Nahrungsergänzungspräparat, von dem eine Kapsel S00 mg Fettsäureethylester, davon mindestens 90% Omega-3-Fettsäuren (Eicosapentaensäure und Docosahexaensäure zusammen 80%, Stearidonsäure und Henei­ cosapentaensäure zusammen 10%). Rest hauptsächlich andere ungesättigte Fettsäuren, enthielt.A nutritional supplement, one of which was used in the test subjects Capsule S00 mg of fatty acid ethyl ester, of which at least 90% omega-3 fatty acids (Eicosapentaenoic acid and docosahexaenoic acid together 80%, stearidonic acid and Henei cosapentaenoic acid together 10%). Rest mainly other unsaturated fatty acids, contained.

Die verabreichte Dosis betrug jeweils 1 bis 3 Kapseln pro Tag.The dose administered was 1 to 3 capsules per day.

In Betracht kommt ferner das oben bereits erwähnte Arzneimittel. In diesem enthält eine Kapsel 500 mg Lachsöl-Konzentrat (18% Eicosapentaensäure, 12% Docosahexaensäure, Omega-3-Fettsäuren insgesamt mindestens 35%, Tocopherol (Vitamin E) 1 mg); sonstige Bestandteile: Tocopherolacetat, Gelatine, Glycerol.The medicament already mentioned above can also be considered. In this one contains Capsule 500 mg salmon oil concentrate (18% eicosapentaenoic acid, 12% docosahexaenoic acid, Total omega-3 fatty acids at least 35%, tocopherol (vitamin E) 1 mg); other Ingredients: tocopherol acetate, gelatin, glycerol.

Claims (4)

1. Verwendung mindestens einer mehrfach ungesättigten Fettsäure und/oder mindestens einer Verbindung einer solchen Fettsäure zur therapeutischen Behandlung von Inkonti­ nenz.1. Use of at least one polyunsaturated fatty acid and / or at least a compound of such a fatty acid for the therapeutic treatment of incontinence nence. 2. Verwendung nach Anspruch 1 mindestens einer Omega-3-Fettsäure und/oder mindestens einer Verbindung einer Omega-3-Fettsäure.2. Use according to claim 1 at least one omega-3 fatty acid and / or at least a compound of an omega-3 fatty acid. 3. Verwendung nach Anspruch 2 von Stearidonsäure, Eicosatetraensäure, Eicosapentaen­ säure, Docosapentaensäure und/oder Docosahexaensäure und/oder mindestens einer Verbindung mindestens einer dieser Säuren.3. Use according to claim 2 of stearidonic acid, eicosatetraenoic acid, eicosapentaen acid, docosapentaenoic acid and / or docosahexaenoic acid and / or at least one Compound at least one of these acids. 4. Verwendung nach einem der Ansprüche 1 bis 3 von Äthylester(n) als der der genannten Verbindung(en).4. Use according to any one of claims 1 to 3 of ethyl ester (s) as that of those Links).
DE2000119052 2000-02-11 2000-04-18 Use of polyunsaturated fatty acids for the treatment of enuresis and incontinence Withdrawn DE10019052A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE10006836A DE10006836B4 (en) 2000-04-18 2000-02-11 Use of omega-3 fatty acids and / or compounds of omega-3 fatty acids
DE2000119052 DE10019052A1 (en) 2000-02-11 2000-04-18 Use of polyunsaturated fatty acids for the treatment of enuresis and incontinence
EP01108445A EP1147769A3 (en) 2000-04-18 2001-04-04 Use of polyunsaturated fatty acids, especially omega-3-fatty acids, for the treatment of enuresis and incontinence

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10006836A DE10006836B4 (en) 2000-04-18 2000-02-11 Use of omega-3 fatty acids and / or compounds of omega-3 fatty acids
DE2000119052 DE10019052A1 (en) 2000-02-11 2000-04-18 Use of polyunsaturated fatty acids for the treatment of enuresis and incontinence

Publications (1)

Publication Number Publication Date
DE10019052A1 true DE10019052A1 (en) 2001-10-25

Family

ID=26004352

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2000119052 Withdrawn DE10019052A1 (en) 2000-02-11 2000-04-18 Use of polyunsaturated fatty acids for the treatment of enuresis and incontinence

Country Status (1)

Country Link
DE (1) DE10019052A1 (en)

Similar Documents

Publication Publication Date Title
DE3926658C2 (en) Fatty acid composition
DE68911103T2 (en) Use of fatty acids for the treatment of myalgic encephalomyelitis.
DE69634693T2 (en) MULTIPLE UNSATURATED OMEGA-3 FATTY ACIDS FOR THE TREATMENT OF INFLAMMATORY ENDURANCE IN CAPSULES WITH TIME DEPENDENT RELEASE
DE4133694C2 (en) Use of an emulsion with polyunsaturated fatty acids for i.v. administration for the treatment of skin diseases
US5198468A (en) Essential fatty acid composition
EP0347056B1 (en) Essential fatty acid compositions
DE3486339T2 (en) Pharmaceutical and dietary composition.
DE69315020T2 (en) Use of fatty acids to increase calcium absorption in the intestine
DE60212786T2 (en) Use of polyunsaturated fatty acids for the primary prevention of cardiovascular events
DE69907010T2 (en) COMPOSITION CONTAINING UBICHINONE SUITABLE FOR PROMOTING THE INCREASED INTRAMITOCHONDRIAL TRANSPORTATION OF UBICHINONES AND METHODS OF USE THEREOF
DE3687347T2 (en) FAST-ACTING, INTRAVENOUS EMULSIONS OF OMEGA-3 FATTY ACID ESTERS.
DE60022987T2 (en) Fatty acid composition containing at least 80% by weight of EPA and DHA
DE60000133T2 (en) ESSENTIAL FATTY ACIDS FOR PREVENTING CARDIOVASCULAR SEASONS
DE2905979C2 (en) Use of acetylated, distilled monoglycerides for the treatment of lipid metabolic disorders in humans
CA1310911C (en) Essential fatty acid compositions
EP0524796B1 (en) Use of essential fatty acids in the preparation of a medicament for the treatment of AIDS
JPH06128154A (en) Food composition
EP0734723A1 (en) Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis
DE69821524T2 (en) USE OF VITIS VINIFERA EXTRACTS PHOSPHOLIPIDE COMPLEX AS ANTIATHEROSCLEROTIC AGENTS
DE69118130T2 (en) food
DE69025787T2 (en) Prophylaxis for atopy
DE60026644T2 (en) Use of ferulic acid for the treatment of hypertension
DE19930030B4 (en) Oral dosage form containing CO-3-unsaturated fatty acids
EP0273407B1 (en) Medicine for improving the specific properties of blood
DE10006836B4 (en) Use of omega-3 fatty acids and / or compounds of omega-3 fatty acids

Legal Events

Date Code Title Description
AF Is addition to no.

Ref document number: 10006836

Country of ref document: DE

AF Is addition to no.

Ref document number: 10006836

Country of ref document: DE

8110 Request for examination paragraph 44
8127 New person/name/address of the applicant

Owner name: NEURONET INSTITUT FUER HIRNFORSCHUNG & ANGEWAN, DE

Owner name: K. D. PHARMA BEXBACH GMBH, 66450 BEXBACH, DE

8162 Independent application
R082 Change of representative

Representative=s name: PATENTANWAELTE BERNHARDT/WOLFF PARTNERSCHAFT, DE

Representative=s name: PATENTANWAELTE BERNHARDT/WOLFF PARTNERSCHAFT M, DE

R016 Response to examination communication
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee